Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Shumway Capital

Founders Chris Shumway

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 11
Average round size
info
The average size of a deal this fund participated in
$45M
Portfolio companies 5
Rounds per year 0.92
Lead investments 1
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.55
Exits 1
Key employees 4
Stages of investment
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Medical
  • Pharmaceutical
  • Health Care
  • Clinical Trials
Summary

Shumway Capital is the famous VC, which was founded in 2011. The venture was found in North America in United States. The main department of described VC is located in the Greenwich.

Among the most popular portfolio startups of the fund, we may highlight Finch Therapeutics Group, Vedanta Biosciences, Artsy. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in a number of founders of portfolio startups. Among the most popular fund investment industries, there are Banking, Pharmaceutical. Besides, a startup needs to be aged 11-15 years to get the investment from the fund.

The fund is constantly included in less than 2 deals per year. The real fund results show that this VC is 23 percentage points more often commits exit comparing to other companies. The common things for fund are deals in the range of 10 - 50 millions dollars. The average startup value when the investment from Shumway Capital is 100-500 millions dollars. The high activity for fund was in 2019.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Shumway Capital, startups are often financed by Thrive Capital, ZhenFund, Willett Advisors LLC. The meaningful sponsors for the fund in investment in the same round are Avenir Growth Capital, Willett Advisors LLC, Noro-Moseley Partners. In the next rounds fund is usually obtained by Symbiosis, Noro-Moseley Partners, Hatteras Venture Partners.

The fund was created by Chris Shumway. Besides them, we counted 4 critical employees of this fund in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Shumway Capital:
Typical Co-investors
Shumway Capital is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Shumway Capital:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
CITIC Group Corporation Beijing, Beijing, China
Citius -
Golden Equator Capital Central Region, Singapore, Singapore
Map Master Aichi Prefecture, Japan, Nagoya
Peilin Nengyuan Touzi China, Fujian, Hunan
Quilvest Luxembourg, Luxembourg
Sandbox Insurtech Ventures Chicago, Illinois, United States
Vietnam Innovative Startup Accelerator Chicago, Illinois, United States
Watershed Capital Austin, Texas, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Finch Therapeutics

Biotechnology
Clinical Trials
Machine Learning
Therapeutics
$53M21 Aug 2019 Massachusetts, United States

Vedanta Biosciences

Biotechnology
Business Development
Drug Discovery
Medical
$18M13 May 2019 Cambridge, Massachusetts, United States

Elligo Health Research

Biotechnology
Health Care
Medical
Pharmaceutical
$20M07 May 2019 Austin, Texas, United States

Elligo Health Research

Biotechnology
Health Care
Medical
Pharmaceutical
$16M20 Mar 2018 Austin, Texas, United States

Finch Therapeutics

Biotechnology
Clinical Trials
Machine Learning
Therapeutics
$36M01 Mar 2018 Massachusetts, United States

Elligo Health Research

Biotechnology
Health Care
Medical
Pharmaceutical
01 Mar 2016 Austin, Texas, United States

Trumid

Banking
Electronics
Finance
Financial Services
FinTech
Trading Platform
$8M04 Mar 2015 New York, United States
News
Elligo Health Research Inks $135M Series E

– Elligo Health Research, a healthcare-enabling research organization powered by the novel IntElligo technology, announced a $135m Series E financing round.
Morgan Stanley Expansion Capital and Ally Bridge Group participated in the financing round.
– The round was also participated by Norwest Venture Partners and all major existing investors, including Cerner, Hatteras Venture Partners, Noro-Moseley Partners, Piper Sandler Merchant Banking, Shumway Capital, and Syneos Health.
– This financing allows Elligo to invest further in its technology platform and leverage data in new ways to address current challenges in the clinical trial industry.

Vedanta Biosciences Raises $68M in Series D Financing

– Vedanta Biosciences, Inc. from Cambridge, MA develops new category of oral therapies using defined bacterial consortia manufactured from clonal cell banks.
– The company closed a $68m Series D financing.
– The round was led by affiliates of Magnetar Capital with participation from Verition Fund Management, Fosun Health Capital, co-founder PureTech Health (Nasdaq: PRTC, LSE: PRTC), Rock Springs Capital, Skyviews Life Science, JSR Corporation, SymBiosis LLC, Shumway Capital, Health for Life Capital (Seventure Partners), and other institutional investors.
– The company plans to use the funds to advance its pipeline of defined bacterial consortia, including progressing VE303 into a Phase 3 clinical trial in patients at high risk for recurrentCDI, initiating a Phase 2 clinical trial of VE202 in mild to moderate ulcerative colitis, and continuing to advance programs in additional indications.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Shumway Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 11
Average round size 45M
Rounds per year 0.92
Peak activity year 2019
Lead investments 1
Follow on index 0.55
Exits 1
Group Appearance index 0.82

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Finch Therapeutics

Biotechnology
Clinical Trials
Machine Learning
Therapeutics
$53M21 Aug 2019 Massachusetts, United States

Vedanta Biosciences

Biotechnology
Business Development
Drug Discovery
Medical
$18M13 May 2019 Cambridge, Massachusetts, United States

Elligo Health Research

Biotechnology
Health Care
Medical
Pharmaceutical
$20M07 May 2019 Austin, Texas, United States

Elligo Health Research

Biotechnology
Health Care
Medical
Pharmaceutical
$16M20 Mar 2018 Austin, Texas, United States

Finch Therapeutics

Biotechnology
Clinical Trials
Machine Learning
Therapeutics
$36M01 Mar 2018 Massachusetts, United States

Elligo Health Research

Biotechnology
Health Care
Medical
Pharmaceutical
01 Mar 2016 Austin, Texas, United States

Trumid

Banking
Electronics
Finance
Financial Services
FinTech
Trading Platform
$8M04 Mar 2015 New York, United States
Crunchbase icon

Content report

The following text will be sent to our editors: